Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Growth (Status and Outlook) 2024-2030

Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Growth (Status and Outlook) 2024-2030

GLP-1 agonists are a class of pharmaceutical agents used to treat both type 2 diabetes mellitus and obesity,including semaglutide,liraglutide,tirzepatide,and others,which can stimulate GLP-1 receptors,leading to increased insulin secretion in response to meals,decreased glucagon release,and slowed gastric emptying.While GLP-1 agonists can also promote weight loss by enhancing feelings of fullness and decreasing appetite.

The global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LPI (LP Information)' newest research report, the “GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Forecast” looks at past sales and reviews total world GLP-1 Agonists for the Treatment of both Diabetes and Obesity sales in 2022, providing a comprehensive analysis by region and market sector of projected GLP-1 Agonists for the Treatment of both Diabetes and Obesity sales for 2023 through 2029. With GLP-1 Agonists for the Treatment of both Diabetes and Obesity sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world GLP-1 Agonists for the Treatment of both Diabetes and Obesity industry.

This Insight Report provides a comprehensive analysis of the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on GLP-1 Agonists for the Treatment of both Diabetes and Obesity portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for GLP-1 Agonists for the Treatment of both Diabetes and Obesity and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity.

United States market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key GLP-1 Agonists for the Treatment of both Diabetes and Obesity players cover Novo Nordisk, Eli Lilly, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of GLP-1 Agonists for the Treatment of both Diabetes and Obesity market by product type, application, key players and key regions and countries.

Segmentation by Type:
Semaglutide
Liraglutide
Tirzepatide

Segmentation by Application:
Hospital and Clinic
Retail Pharmacies
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Semaglutide
Liraglutide
Tirzepatide

Segmentation by Application:
Hospital and Clinic
Retail Pharmacies
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novo Nordisk
Eli Lilly

Please note: The report will take approximately 2 business days to prepare and deliver.